share_log

Duckhorn Portfolio Analyst Ratings

Benzinga ·  Oct 12, 2023 14:03
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/12/2023 23.9% Barclays $14 → $12 Maintains Overweight
09/29/2023 44.55% Barclays $16 → $14 Maintains Overweight
09/25/2023 96.18% RBC Capital $23 → $19 Maintains Outperform
09/05/2023 44.55% BMO Capital → $14 Initiates Coverage On → Market Perform
08/15/2023 85.85% B of A Securities $20 → $18 Maintains Buy
07/20/2023 65.2% Barclays $17 → $16 Maintains Overweight
06/14/2023 96.18% Wedbush → $19 Reiterates Outperform → Outperform
06/09/2023 137.48% RBC Capital → $23 Reiterates Outperform → Outperform
06/09/2023 96.18% Wedbush → $19 Reiterates Outperform → Outperform
06/06/2023 137.48% RBC Capital → $23 Reiterates Outperform → Outperform
06/05/2023 75.53% JP Morgan $18 → $17 Maintains Neutral
03/09/2023 85.85% JP Morgan $17 → $18 Maintains Neutral
12/12/2022 96.18% Barclays $18 → $19 Maintains Equal-Weight
10/11/2022 85.85% Wedbush → $18 Initiates Coverage On → Outperform
09/30/2022 85.85% Barclays $19 → $18 Maintains Equal-Weight
09/22/2022 106.5% Credit Suisse $26 → $20 Maintains Outperform
09/22/2022 96.18% Barclays $21 → $19 Maintains Equal-Weight
09/15/2022 96.18% JP Morgan $24 → $19 Downgrades Overweight → Neutral
09/14/2022 137.48% Jefferies $28 → $23 Maintains Buy
06/06/2022 116.83% Barclays $20 → $21 Maintains Equal-Weight
03/28/2022 137.48% RBC Capital → $23 Upgrades Sector Perform → Outperform
03/15/2022 106.5% Barclays $19 → $20 Maintains Equal-Weight
03/10/2022 96.18% Barclays $22 → $19 Maintains Equal-Weight
12/14/2021 168.46% Credit Suisse $25 → $26 Maintains Outperform
12/10/2021 127.16% Barclays $21 → $22 Maintains Equal-Weight
10/05/2021 189.11% Citigroup $25 → $28 Maintains Buy
10/05/2021 158.13% Credit Suisse $23 → $25 Maintains Outperform
10/05/2021 137.48% RBC Capital $22 → $23 Maintains Sector Perform
06/08/2021 137.48% Credit Suisse $21 → $23 Maintains Outperform
04/12/2021 106.5% JP Morgan → $20 Initiates Coverage On → Overweight
04/12/2021 127.16% Jefferies → $22 Initiates Coverage On → Buy
04/12/2021 116.83% B of A Securities → $21 Initiates Coverage On → Buy
04/12/2021 85.85% Barclays → $18 Initiates Coverage On → Equal-Weight
04/12/2021 96.18% RBC Capital → $19 Initiates Coverage On → Sector Perform
04/12/2021 116.83% Credit Suisse → $21 Initiates Coverage On → Outperform
04/12/2021 127.16% Evercore ISI Group → $22 Initiates Coverage On → Outperform
04/12/2021 127.16% Citigroup → $22 Initiates Coverage On → Buy

What is the target price for Duckhorn Portfolio (NAPA)?

The latest price target for Duckhorn Portfolio (NYSE: NAPA) was reported by Barclays on October 12, 2023. The analyst firm set a price target for $12.00 expecting NAPA to rise to within 12 months (a possible 23.90% upside). 13 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Duckhorn Portfolio (NAPA)?

The latest analyst rating for Duckhorn Portfolio (NYSE: NAPA) was provided by Barclays, and Duckhorn Portfolio maintained their overweight rating.

When is the next analyst rating going to be posted or updated for Duckhorn Portfolio (NAPA)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Duckhorn Portfolio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Duckhorn Portfolio was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.

Is the Analyst Rating Duckhorn Portfolio (NAPA) correct?

While ratings are subjective and will change, the latest Duckhorn Portfolio (NAPA) rating was a maintained with a price target of $14.00 to $12.00. The current price Duckhorn Portfolio (NAPA) is trading at is $9.69, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment